Our study found that proxalutamide can synergistically block the SREBP-1/FASN/lipogenesis and AR signal axis of PCa cells, which provides new insight into the underlying molecular basis of the superior therapeutic activity of proxalutamide in PCa. The gene discussed is AR; the disease is posterior cortical atrophy.